|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.70 USD | -2.04% |
|
-3.50% | +4.47% |
| 06-19 | FTSE 100 flat as investors weigh US-Iran peace talks, energy stocks support | RE |
| 06-18 | Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine |  |
| Market Cap | 76.72B 102B 88.49B 81.91B 144B 9,574B 145B 973B 377B 4,714B 381B 373B 16,378B | P/E 2026 * |
12.4x | P/E 2027 * | 11.4x |
|---|---|---|---|---|---|
| Enterprise Value | 90.98B 120B 105B 97.13B 170B 11,353B 172B 1,154B 447B 5,590B 451B 442B 19,420B | EV / Sales 2026 * |
2.69x | EV / Sales 2027 * | 2.48x |
| Free-Float |
92.29% | Yield 2026 * |
3.64% | Yield 2027 * | 3.81% |
Last Transcript: GSK plc
| 1 day | -2.04% | ||
| 1 week | -3.50% | ||
| Current month | -1.15% | ||
| 1 month | +0.02% | ||
| 3 months | -1.44% | ||
| 6 months | +6.95% | ||
| Current year | +4.47% |
| 1 week | 25.21 |  | 26.3 |
| 1 month | 23.46 | | 26.63 |
| Current year | 22.75 | | 31.48 |
| 1 year | 17.15 | | 31.48 |
| 3 years | 15.54 | | 31.48 |
| 5 years | 13.48 | | 31.48 |
| 10 years | 13.48 | | 31.48 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.04% | -3.50% | - | - | 101B | |
| -1.21% | -3.04% | +44.03% | +143.07% | 980B | |
| -2.48% | -5.18% | +52.47% | +39.15% | 550B | |
| -2.14% | -4.94% | +16.83% | +57.08% | 382B | |
| +0.25% | -3.09% | +23.33% | +16.04% | 316B | |
| +0.61% | -1.69% | +27.35% | +13.73% | 272B | |
| +0.22% | -3.10% | +24.67% | +30.49% | 268B | |
| +4.59% | +1.98% | -38.43% | -46.26% | 199B | |
| -1.19% | -4.95% | +16.68% | +47.69% | 182B | |
| -1.35% | -1.46% | +14.06% | +59.26% | 154B | |
| Average | -0.47% | -3.02% | +20.11% | +40.03% | 366.93B | |
| Weighted average by Cap. | -0.82% | -3.68% | +29.49% | +63.31% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.79B 44.72B 38.97B 36.08B 63.29B 4,217B 63.77B 429B 166B 2,076B 168B 164B 7,214B | 35.48B 46.94B 40.92B 37.88B 66.44B 4,427B 66.94B 450B 174B 2,180B 176B 172B 7,573B |
| Net income | 6.27B 8.29B 7.23B 6.69B 11.74B 782B 11.82B 79.46B 30.77B 385B 31.09B 30.45B 1,338B | 6.67B 8.82B 7.69B 7.12B 12.49B 832B 12.58B 84.57B 32.75B 410B 33.09B 32.41B 1,424B |
| Net Debt | 14.25B 18.86B 16.44B 15.22B 26.69B 1,778B 26.89B 181B 69.99B 876B 70.72B 69.26B 3,042B | 11.19B 14.81B 12.9B 11.95B 20.96B 1,396B 21.11B 142B 54.95B 688B 55.52B 54.38B 2,388B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-06-18 | 25.70 $ | -2.04% | 576 |
| 26-06-17 | 26.24 $ | +3.90% | 1,561 |
| 26-06-16 | 25.25 $ | -0.98% | 270 |
| 26-06-15 | 25.50 $ | -4.25% | 380 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
- GLAXF Stock
Select your edition
All financial news and data tailored to specific country editions
